Show simple item record

dc.contributor.authorPerez-Lopez, R
dc.contributor.authorLorente, D
dc.contributor.authorBlackledge, MD
dc.contributor.authorCollins, DJ
dc.contributor.authorMateo, J
dc.contributor.authorBianchini, D
dc.contributor.authorOmlin, A
dc.contributor.authorZivi, A
dc.contributor.authorLeach, MO
dc.contributor.authorde Bono, JS
dc.contributor.authorKoh, D-M
dc.contributor.authorTunariu, N
dc.date.accessioned2016-12-12T13:40:02Z
dc.date.issued2016-07
dc.identifier.citationRadiology, 2016, 280 (1), pp. 151 - 160
dc.identifier.issn0033-8419
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/323
dc.identifier.eissn1527-1315
dc.identifier.doi10.1148/radiol.2015150799
dc.description.abstractPurpose To determine the correlation between the volume of bone metastasis as assessed with diffusion-weighted (DW) imaging and established prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) and the association with overall survival (OS). Materials and Methods This retrospective study was approved by the institutional review board; informed consent was obtained from all patients. The authors analyzed whole-body DW images obtained between June 2010 and February 2013 in 53 patients with mCRPC at the time of starting a new line of anticancer therapy. Bone metastases were identified and delineated on whole-body DW images in 43 eligible patients. Total tumor diffusion volume (tDV) was correlated with the bone scan index (BSI) and other prognostic factors by using the Pearson correlation coefficient (r). Survival analysis was performed with Kaplan-Meier analysis and Cox regression. Results The median tDV was 503.1 mL (range, 5.6-2242 mL), and the median OS was 12.9 months (95% confidence interval [CI]: 8.7, 16.1 months). There was a significant correlation between tDV and established prognostic factors, including hemoglobin level (r = -0.521, P < .001), prostate-specific antigen level (r = 0.556, P < .001), lactate dehydrogenase level (r = 0.534, P < .001), alkaline phosphatase level (r = 0.572, P < .001), circulating tumor cell count (r = 0.613, P = .004), and BSI (r = 0.565, P = .001). A higher tDV also showed a significant association with poorer OS (hazard ratio, 1.74; 95% CI: 1.02, 2.96; P = .035). Conclusion Metastatic bone disease from mCRPC can be evaluated and quantified with whole-body DW imaging. Whole-body DW imaging-generated tDV showed correlation with established prognostic biomarkers and is associated with OS in mCRPC. (©) RSNA, 2016 Online supplemental material is available for this article.
dc.formatPrint-Electronic
dc.format.extent151 - 160
dc.languageeng
dc.language.isoeng
dc.subjectBone and Bones
dc.subjectHumans
dc.subjectBone Neoplasms
dc.subjectDiffusion Magnetic Resonance Imaging
dc.subjectDisease-Free Survival
dc.subjectTumor Burden
dc.subjectProportional Hazards Models
dc.subjectRetrospective Studies
dc.subjectReproducibility of Results
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectWhole Body Imaging
dc.subjectKaplan-Meier Estimate
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.titleVolume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.1148/radiol.2015150799
rioxxterms.licenseref.startdate2016-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfRadiology
pubs.issue1
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume280
pubs.embargo.terms12 months
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamComputational Imagingen_US
icr.researchteamMagnetic Resonanceen_US
dc.contributor.icrauthorLeach, Martinen
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorKoh, Dow-Muen
dc.contributor.icrauthorBlackledge, Matthewen
dc.contributor.icrauthorTunariu, Ninaen
dc.contributor.icrauthorMateo Valderrama, Joaquinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record